Halozyme Therapeutics, Inc. (HALO) is among the top undervalued biotech stocks to buy now, with a raised price target of $75 from $72 by H.C. Wainwright analyst Mitchell Kapoor. The company reported fiscal Q2 2025 results, with total revenue up 41% year-over-year to $326 million and net income rising 77% year-over-year to $165 million.

Analyst Mitchell Kapoor raised Halozyme Therapeutics, Inc.’s fiscal 2025 guidance for the third time this year following solid results. The company’s royalty revenue also grew 65% year-over-year to $206 million, while adjusted EBITDA increased 65% year-over-year to $226 million. Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company specializing in drug-device combination products.

The company’s products offer increased patient comfort, adherence, and convenience benefits. While HALO shows promise as an investment, other AI stocks may offer greater upside potential with less downside risk. For more information on undervalued AI stocks, see Insider Monkey’s report. Halozyme Therapeutics, Inc.’s strong performance in Q2 2025 positions it as a potential growth stock to invest in now.

Read more at Yahoo Finance: H.C. Wainwright Lifts PT on Halozyme Therapeutics (HALO) to $75 From $72